Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell–mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
Open Access
- 28 May 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 113 (22), 5549-5557
- https://doi.org/10.1182/blood-2008-06-165068
Abstract
Phosphoinositide 3-kinases (PI3Ks) are among the most frequently activated signaling pathways in cancer. In chronic lymphocytic leukemia (CLL), signals from theKeywords
This publication has 71 references indexed in Scilit:
- Bcl-2–family proteins and hematologic malignancies: history and future prospectsBlood, 2008
- The regulation of cell motility and chemotaxis by phospholipid signalingJournal of Cell Science, 2008
- New insights into PTENJournal of Cell Science, 2007
- Recognizing and exploiting differences between RNAi and small-molecule inhibitorsNature Chemical Biology, 2007
- Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cellsLeukemia Research, 2007
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutationsLeukemia, 2005
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathwayBlood, 2005